Delving into the Latest Updates on Taxolog, Inc. with Synapse

Overview

Milataxel is a new taxane that may have several advantages over the currently available taxanes. The current study is designed to determine the response rate of oral Milataxel in patients with malignant Mesothelioma. The study specifically targets patients who have recurring or progressive disease following previous chemotherapy.

Start Date01 Mar 2008

Sponsor / Collaborator

Taxolog, Inc.

100 Clinical Results associated with Taxolog, Inc.

Login to view more data

0 Patents (Medical) associated with Taxolog, Inc.

Login to view more data

4

Literatures (Medical) associated with Taxolog, Inc.

01 Jun 2009·Anti-Cancer Agents in Medicinal ChemistryQ4 · MEDICINE

Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?

Q4 · MEDICINE

Review

Author: Monteiro, Alvaro N. A. ; DeLigio, J. Thomas ; Velkova, Aneliya ; Zorio, Diego A. R.

Taxanes (paclitaxel and docetaxel) are currently used to treat ovarian, breast, lung, and head and neck cancers. Despite its clinical success taxane-based treatment could be significantly improved by identifying those patients whose tumors are more likely to present a clinical response. In this mini-review we discuss the accumulating evidence indicating that the breast and ovarian cancer susceptibility gene product BRCA1 mediates cellular response to taxanes. We review data from in vitro, animal, and clinical studies, and discuss them in context of response to therapy. We argue that levels of BRCA1 in tumors may provide a predictive marker for the response to treatment with taxanes. In addition, the study of the role of BRCA1 in the mechanism of action of taxanes might reveal alternative approaches to avoid resistance.

01 Jul 2008·Lab AnimalQ1 · AGRICULTURAL & FORESTRY SCIENCE

Response to Protocol Review Scenario: More references required

Q1 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Arrington, Heather A

15 Jul 2004·Journal of Clinical Oncology

Phase 1 trial of oral MAC-321 in subjects with advanced malignant solid tumors

Author: Cohen, M. ; Wang, K. K. ; Shapiro, M. ; Bukowski, R. ; Lockhart, A. C. ; Zhu, A. X. ; Grover, J. ; Cooper, W. ; Rothenberg, M. L. ; Appleman, L.

100 Deals associated with Taxolog, Inc.

Login to view more data

100 Translational Medicine associated with Taxolog, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 21 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

TL-1892	Neoplasms More	Discontinued
TL-1836	Neoplasms More	Discontinued
Milataxel ( Tubulin )	Mesothelioma, Malignant More	Pending
TL-310 ( Tubulin )	Neoplasms More	Pending
Simotaxel ( Tubulin )	Solid tumor More	Pending